Uniunea Europeană - slovenă - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovarijske neoplazme - antineoplastična sredstva - ciste na cancerlynparza je označen kot monotherapy za:vzdrževanje zdravljenje odraslih bolnikov z napredovalim (figo fazah iii in iv) brca1/2-mutiral (germline in/ali somatski) high-grade epitelnih jajčnikov, fallopian tube ali primarni trebušno raka, ki so v odziv (popolna ali delna) po koncu prve vrstice platinum, ki temelji kemoterapijo. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 in 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. bolniki morajo imeti predhodno že bili zdravljeni z anthracycline in taxane v (neo)adjuvant ali metastatskim nastavitev, če bolniki niso bili primerni za temi postopki (glej točko 5. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je treba tudi napredovala na ali po predhodnem endokrine terapije, ali neprimerna za endokrine terapija. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Uniunea Europeană - slovenă - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatične neoplazme - terapevtski radiofarmacevtiki - xofigo je indicirano za zdravljenje odraslih s kastracijo-ki se upira raka prostate, simptomatsko kosti metastaz in ni znano visceralno metastaz.

Uniunea Europeană - slovenă - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 in 5.

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

riemser pharma gmbh - spironolakton - obložena tableta - spironolakton 25 mg / 1 tableta - spironolakton

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

riemser pharma gmbh - spironolakton - obložena tableta - spironolakton 50 mg / 1 tableta - spironolakton

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

riemser pharma gmbh - spironolakton - kapsula, trda - spironolakton 100 mg / 1 kapsula - spironolakton

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kabazitaksel - koncentrat za raztopino za infundiranje - kabazitaksel 10 mg / 1 ml - kabazitaksel

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kabazitaksel - koncentrat za raztopino za infundiranje - kabazitaksel 10 mg / 1 ml - kabazitaksel

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kabazitaksel - koncentrat za raztopino za infundiranje - kabazitaksel 10 mg / 1 ml - kabazitaksel

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kabazitaksel - koncentrat za raztopino za infundiranje - kabazitaksel 10 mg / 1 ml - kabazitaksel